INTRODUCTION: It has been shown that phosphodiesterase type 5 (PDE5) inhibitors preserve smooth muscle (SM) content and ameliorate the fibrotic degeneration normally seen in the corpora cavernosa after bilateral cavernosal nerve resection (BCNR). However, the downstream mechanisms by which these drugs protect the corpora cavernosa remain poorly understood. AIM: To provide insight into the mechanism, we aimed to determine the gene expression profile of angiogenesis-related pathways within the penile tissue after BCNR with or without continuous sildenafil (SIL) treatment. METHODS: Five-month-old Fisher rats were subjected to BCNR or sham operation and treated with or without SIL (20 mg/kg/BW drinking water) for 3 days or 45 days (N = 8 rats per group). Total RNAs isolated from the denuded penile shaft and prostate were subjected to reverse transcription and to angiogenesis real-time-polymerase chain reaction arrays (84 genes). Changes in protein expression of selected genes such as epiregulin (EREG) and connective tissue growth factor (CTGF) were corroborated by Western blot and immunohistochemistry. MAIN OUTCOMES MEASURES: Genes modulated by BCNR and SIL treatment. RESULTS: A decreased expression of genes related to SM growth factors such as EREG, platelet-derived growth factor (PDGF), extracellular matrix regulators such as metalloproteinases 3 and 9, endothelial growth factors, together with an upregulation of pro-fibrotic genes such as CTGF and transforming growth factor beta 2 were found at both time points after BCNR. SIL treatment reversed this process by upregulating endothelial and SM growth factors and downregulating pro-fibrotic factors. SIL did not affect the expression of EREG, VEGF, and PDGF in the ventral prostate of BCNR animals. CONCLUSIONS: SIL treatment after BCNR activates genes related to SM preservation and downregulates genes related to fibrosis in the corpora cavernosa. These results provide a mechanistic justification for the use of SIL and other PDE5 inhibitors as protective therapy against corporal SM loss and fibrosis after radical prostatectomy.
INTRODUCTION: It has been shown that phosphodiesterase type 5 (PDE5) inhibitors preserve smooth muscle (SM) content and ameliorate the fibrotic degeneration normally seen in the corpora cavernosa after bilateral cavernosal nerve resection (BCNR). However, the downstream mechanisms by which these drugs protect the corpora cavernosa remain poorly understood. AIM: To provide insight into the mechanism, we aimed to determine the gene expression profile of angiogenesis-related pathways within the penile tissue after BCNR with or without continuous sildenafil (SIL) treatment. METHODS: Five-month-old Fisher rats were subjected to BCNR or sham operation and treated with or without SIL (20 mg/kg/BW drinking water) for 3 days or 45 days (N = 8 rats per group). Total RNAs isolated from the denuded penile shaft and prostate were subjected to reverse transcription and to angiogenesis real-time-polymerase chain reaction arrays (84 genes). Changes in protein expression of selected genes such as epiregulin (EREG) and connective tissue growth factor (CTGF) were corroborated by Western blot and immunohistochemistry. MAIN OUTCOMES MEASURES: Genes modulated by BCNR and SIL treatment. RESULTS: A decreased expression of genes related to SM growth factors such as EREG, platelet-derived growth factor (PDGF), extracellular matrix regulators such as metalloproteinases 3 and 9, endothelial growth factors, together with an upregulation of pro-fibrotic genes such as CTGF and transforming growth factor beta 2 were found at both time points after BCNR. SIL treatment reversed this process by upregulating endothelial and SM growth factors and downregulating pro-fibrotic factors. SIL did not affect the expression of EREG, VEGF, and PDGF in the ventral prostate of BCNR animals. CONCLUSIONS:SIL treatment after BCNR activates genes related to SM preservation and downregulates genes related to fibrosis in the corpora cavernosa. These results provide a mechanistic justification for the use of SIL and other PDE5 inhibitors as protective therapy against corporal SM loss and fibrosis after radical prostatectomy.
Authors: Biljana Musicki; Hunter C Champion; Robyn E Becker; Melissa F Kramer; Tongyun Liu; Sena F Sezen; Arthur L Burnett Journal: J Urol Date: 2005-10 Impact factor: 7.450
Authors: Yvonne A Bremer; Fadi Salloum; Ramzi Ockaili; Eric Chou; William B Moskowitz; Rakesh C Kukreja Journal: Pediatr Res Date: 2004-11-05 Impact factor: 3.756
Authors: Biljana Musicki; Hunter C Champion; Robyn E Becker; Tongyun Liu; Melissa F Kramer; Arthur L Burnett Journal: Mol Pharmacol Date: 2005-04-25 Impact factor: 4.436
Authors: D S Taylor; X Cheng; J E Pawlowski; A R Wallace; P Ferrer; C J Molloy Journal: Proc Natl Acad Sci U S A Date: 1999-02-16 Impact factor: 11.205
Authors: Carmen Berasain; Elena R García-Trevijano; Josefa Castillo; Elena Erroba; Mónica Santamaría; David C Lee; Jesús Prieto; Matías A Avila Journal: J Biol Chem Date: 2005-03-07 Impact factor: 5.157
Authors: Tariq S Hakky; Adam S Baumgarten; Justin Parker; Yin Zheng; Mike Kongnyuy; Daniel Martinez; Rafael E Carrion Journal: Curr Urol Rep Date: 2014-04 Impact factor: 3.092
Authors: Ana Agusti; Vicente Hernández-Rabaza; Tiziano Balzano; Lucas Taoro-Gonzalez; Andrea Ibañez-Grau; Andrea Cabrera-Pastor; Santos Fustero; Marta Llansola; Carmina Montoliu; Vicente Felipo Journal: CNS Neurosci Ther Date: 2017-03-11 Impact factor: 5.243
Authors: Su M Hlaing; Leah A Garcia; Istvan Kovanecz; Ramon A Martinez; Sanjana Shah; Jorge N Artaza; Monica G Ferrini Journal: BJU Int Date: 2012-06-06 Impact factor: 5.588